WEIGHT-LOSS PENS AND BARIATRIC SURGERY IN THE MANAGEMENT OF OBESITY: A COMPARISON BETWEEN INDICATION CRITERIA, THERAPEUTIC EFFECTIVENESS, AND REPERCUSSIONS ON QUALITY OF LIFE
DOI:
https://doi.org/10.63330/aurumpub.049-049Keywords:
Obesity, Bariatric surgery, Semaglutide, Tirzepatide, GLP-1, Quality of lifeAbstract
Obesity is a chronic, multifactorial, and progressive disease associated with high cardiovascular, metabolic, and psychosocial morbidity and mortality. In recent years, advances in GLP-1 receptor agonists and dual GIP/GLP-1 agonists—popularly known as "weight-loss pens"—have significantly modified the clinical treatment of obesity, offering substantial weight loss and relevant metabolic improvement. In parallel, bariatric surgery remains the most effective intervention for sustained weight loss and remission of comorbidities in selected patients. This article reviews and compares the criteria for indication, therapeutic effectiveness, clinical safety, and impact on quality of life between injectable pharmacological therapies and bariatric surgery. The economic impact, therapeutic limitations, risk of weight regain, and the need for a longitudinal multidisciplinary approach are also discussed.
Downloads
References
1. ARTERBURN, David E. et al. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Annals of Internal Medicine, Philadelphia, v. 169, n. 11, p. 741-750, 2018.
2. COURCOULAS, Anita P. et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA, Chicago, v. 310, n. 22, p. 2416-2425, 2013.
3. DAVIES, Melanie et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity. The New England Journal of Medicine, Boston, v. 384, n. 11, p. 989-1002, 2021.
4. FRIED, Marc et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obesity Surgery, New York, v. 24, n. 1, p. 42-55, 2014.
5. JASTREBOFF, Ania M. et al. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, Boston, v. 387, n. 3, p. 205-216, 2022.
6. MECHANICK, Jeffrey I. et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of bariatric surgery patients. Obesity, Silver Spring, v. 28, n. 4, p. 1-58, 2020.
7. RUBINO, Francesco et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care, Arlington, v. 39, n. 6, p. 861-877, 2016.
8. SCHAUER, Philip R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. The New England Journal of Medicine, Boston, v. 376, n. 7, p. 641-651, 2017.
9. WILDING, John P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, Boston, v. 384, n. 11, p. 989-1002, 2021.
10. WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: WHO, 2024. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Acesso em: 18 maio 2026.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
